Cipla Rises on Strong Q1 and U.S. Hopes

  Published 11 months ago

Cipla's profit beat estimates on strong India sales; U.S. launches expected to drive future growth amid mixed analyst views.

  • Cipla shares have gained 5% since results; 14 brokerages raised price targets, median now at Rs 1,723.5.
  • HSBC sees FY26 dip in gRevlimid sales but expects U.S. drug launches to cushion impact.
  • Goldman cautious on growth, Jefferies sees H2FY27 U.S. launches as key for future momentum.

You might like these

UltraTech Q1 Profit Beats Estimates

Urban Company Offers Instant Services

India Seeks Gold Loan Rule Relaxations

BluSmart Faces Insolvency Trouble

RBI Prioritizes Growth Amid Trade Talks

Gold Surges as Tariffs & Uncertainty Rise

Delhivery Acquires Ecom Express Stake Approved

News that matters the most ⚡